INS and Insulin resistance: We followed this with a 6-month randomized controlled clinical trial, the Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET) study, to test the hypothesis that among adults with type 1 diabetes, relative to placebo, the addition of metformin to insulin would decrease hepatic insulin resistance and improve other cardiometabolic measures, without an increase in adverse effects.